Top European VC leads 28-7’s Series A extension with $15 million and brings financing to over $80 million
May 9, 2019 - Sofinnova Partners, a leading European venture capital firm specialized in the life sciences, today announced that the firm led Twentyeight-Seven Therapeutic’s [28-7] Series A extension with a $15 million investment. In addition to Sofinnova Partners, Osage University Partners (OUP) participated in the Series A extension bringing the total Series A financing to $82.75 million.
Twentyeight-Seven Therapeutics Launches with a $65 Million Series A Funding
Sept. 6, 2018 - MPM Capital and Novartis Venture Fund co-led financing to advance lead program targeting a microRNA modulating proteins for the treatment of cancer